CLAIMS

~~1.~~ A mutant v1.13 meningococcal factor H binding protein (fHbp) polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2, wherein the amino acid sequence of ~~said~~ the ~~mutant~~ v1.13 meningococcal fHbp polypeptide ~~includes~~ comprises~~a~~ substitution mutations of SEQ ID NO: 2 including the substitution mutation S216R and substitution mutation E211A. ~~at one or more of residues E211, S216 and E232 of SEQ ID NO: 2.~~

~~2.~~1. ~~The polypeptide of claim 1, wherein the amino acid sequence differs from SEQ ID NO: 2 by at least one or more of the substitutions E211A, S216R and E232A.~~

~~3.~~ The mutant v1.13 meningococcal fHbp polypeptide of claim ~~2~~1, wherein the amino acid sequence comprises substitution mutations of SEQ ID NO: 2 including the substitution mutation ~~at multiple residues selected from the following:~~

~~4. E211A and~~ S216R, the substitution mutation ~~and~~

~~5.~~ E211A, and substitution mutation E232A.

~~6.~~2. ~~The polypeptide of claim 3, wherein the amino acid sequence comprises substitutions at residues E211A and S216R.~~

~~7.~~ The mutant v1.13 meningococcal fHbp polypeptide of claim 4~~1~~, comprising or consisting of the amino acid sequence of SEQ ID NO: 4.

~~8. The polypeptide of claim 3, wherein the amino acid sequence comprises substitutions at residues E211A and E232A.~~

~~9. The polypeptide of claim 6, comprising or consisting of the amino acid sequence of SEQ ID NO: 3.~~

~~10. A mutant v1.15 meningococcal fHbp polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 6, wherein the amino acid sequence of said mutant v1.15 meningococcal fHbp polypeptide includes a substitution mutation at one or more of residues E214, S219 and E235 of SEQ ID NO: 6.~~

~~11. The polypeptide of claim 8, wherein the amino acid sequence differs from SEQ ID NO: 6 by at least one or more of the substitutions E214A, S219R and E235A.~~

~~12. The polypeptide of claim 9, wherein the amino acid sequence comprises substitutions at residues selected from the group consisting of:~~

~~13. S219R~~

~~14. E214A and S219R; and~~

~~15. E214A and E235A.~~

~~16. The polypeptide of any of claims 8 to 10, comprising or consisting of the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.~~

~~17. A fusion polypeptide comprising v1, v2 and v3 meningococcal fHbp polypeptides, wherein the variant fHbp sequences are in the order v2-v3-v1 from N- to C-terminus, and wherein the v1 fHbp polypeptide is a mutant v1.13 fHbp polypeptide according to any of claims 1 to 7 or a mutant v1.15 fHbp polypeptide according to any of claims 8 to 11.~~

~~18. The fusion polypeptide of claim 12, wherein the v1 fHbp polypeptide is a mutant v1.13 fHbp polypeptide according to any of claims 1 to 7.~~

~~19. The fusion polypeptide of claims 12 or 13, wherein:~~

~~20. the v2 fHbp polypeptide is a mutant v2 fHbp polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 12, wherein the v2 fHbp amino acid sequence includes a substitution mutation at residues S32 and L123 of SEQ ID NO:12, and wherein the substitutions are S32V and L123R; and~~

~~21. the v3 fHbp polypeptide is a mutant v3 fHbp polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 15 wherein the v3 fHbp amino acid sequence includes a substitution mutation at residues S32 and L126 of SEQ ID NO: 15, and wherein the substitutions are S32V and L126R.~~

~~22. The fusion polypeptide of claim 14, wherein:~~

~~23. the v2 fHbp polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 16; and/or~~

~~24. the v3 fHbp polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 17.~~

~~25. The fusion polypeptide of any of claims 12 to 15, wherein the v2 and v3 sequences and the v3 and v1 sequences are connected by a glycine-serine linker.~~

~~26. The fusion polypeptide of claim 16, wherein the glycine-serine linker is "GSGGGG".~~

~~27. The fusion polypeptide of any of claims 12 to 17, comprising the amino acid sequence of any of SEQ ID NOS: 18-22.~~

~~28. The fusion polypeptide of any of claims 12 to 18, further comprising the N-terminal amino acid sequence of SEQ ID NO. 34.~~

~~29. An isolated nucleic acid molecule, optionally a plasmid, comprising a nucleotide sequence encoding a mutant v1.13 fHbp polypeptide of any of claims 1 to 7, a mutant v1.15 fHbp polypeptide of any of claims 8 to 11, or a fusion polypeptide of any of claims 12 to 19.~~

~~30. A recombinant host cell transformed with the nucleic acid molecule of claim 20.~~

~~31. An immunogenic composition comprising a mutant v1.13 fHbp polypeptide of any of claims 1 to 7, a mutant v1.15 fHbp polypeptide of any of claims 8 to 11, or a fusion polypeptide of any of claims 12 to 19.~~

~~32. The immunogenic composition of claim 22, further comprising one or more of: a meningococcal NHBA antigen, a meningococcal NadA antigen, a meningococcal fHbp antigen, and meningococcal outer membrane vesicles (OMVs).~~

~~33. The immunogenic composition of claim 23, comprising the 4CMenB composition.~~

~~34. The immunogenic composition of any of claims 22 to 24, further comprising a conjugated capsular saccharide from *N. meningitidis* serogroup A, C, W135 and/or Y.~~

~~35. The immunogenic composition of claim 25, further comprising conjugated capsular saccharides from each of *N. meningitidis* serogroups A, C, W135 and Y.~~

~~36. A method for raising an immune response in a mammal, comprising administering the immunogenic composition of any of claims 22 to 26.~~

~~37. The immunogenic composition of any of claims 22 to 26 for use in medicine.~~

~~38. The immunogenic composition of any of claims 22 to 26 for use as a vaccine.~~

~~39. The immunogenic composition of any of claims 22 to 26 for use in a method of raising an immune response in a mammal.~~

~~40. The immunogenic composition of any of claims 22 to 26 for use in immunizing a mammal against *N. meningitidis* infection.~~

~~41. The method of claim 27 or the immunogenic composition for use according to any of claims 28 to 31, wherein the mammal is a human.~~

~~42.~~3.